Zobrazeno 1 - 10
of 658
pro vyhledávání: '"Ann H. Partridge"'
Autor:
Daniel G. Stover, Roberto Salgado, Oleksander Savenkov, Karla Ballman, Erica L. Mayer, Mark Jesus M. Magbanua, Sherene Loi, Mark Vater, Kristyn Glover, Mark Watson, Yujia Wen, W. Fraser Symmans, Charles Perou, Lisa A. Carey, Ann H. Partridge, Hope S. Rugo
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-5 (2024)
Abstract Association of stromal tumor-infiltrating lymphocytes (sTILs) with survival outcomes among patients with metastatic breast cancer (MBC) remains unclear. The primary objective was to evaluate the association of sTILs with progression-free sur
Externí odkaz:
https://doaj.org/article/83a9a621c06f4389a3a50e11d37a5714
Autor:
Megan E. Tesch, Yue Zheng, Shoshana M. Rosenberg, Philip D. Poorvu, Kathryn J. Ruddy, Rulla Tamimi, Lidia Schapira, Jeffrey Peppercorn, Virginia Borges, Steven E. Come, Craig Snow, Shalender Bhasin, Ann H. Partridge
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-8 (2024)
Abstract Ovarian function suppression (OFS) benefits young women with hormone receptor (HR)-positive breast cancer but they are at risk for ovarian function breakthrough. We assessed endocrine effects of gonadotropin-releasing hormone agonist (GnRHa)
Externí odkaz:
https://doaj.org/article/f3ae8ab8377e4157997d9785ff9388a8
Autor:
Eleonora Pagan, Monica Ruggeri, Nadia Bianco, Eraldo Oreste Bucci, Rossella Graffeo, Markus Borner, Monica Giordano, Lorenzo Gianni, Manuela Rabaglio, Andrea Freschi, Elisabetta Cretella, Elena Seles, Alberto Farolfi, Edda Simoncini, Mariangela Ciccarese, Daniel Rauch, Adolfo Favaretto, Friedemann Honecker, Rossana Berardi, Alessandra Franzetti-Pellanda, Shari Gelber, Ann H. Partridge, Aron Goldhirsch, Vincenzo Bagnardi, Olivia Pagani, Karin Ribi
Publikováno v:
Breast, Vol 77, Iss , Pp 103765- (2024)
Purpose: Although younger age has been negatively associated with persistence to adjuvant endocrine therapy (ET), factors contributing to non-persistence remain poorly understood. We assessed factors associated with non-persistence to ET and describe
Externí odkaz:
https://doaj.org/article/570c5e4f78064981bd0ebc4df466fd94
Autor:
Fatima Cardoso, Shani Paluch-Shimon, Eva Schumacher-Wulf, Leonor Matos, Karen Gelmon, Matti S. Aapro, Jyoti Bajpai, Carlos H. Barrios, Jonas Bergh, Elizabeth Bergsten-Nordström, Laura Biganzoli, Maria João Cardoso, Lisa A. Carey, Mariana Chavez-MacGregor, Runcie Chidebe, Javier Cortés, Giuseppe Curigliano, Rebecca A. Dent, Nagi S. El Saghir, Alexandru Eniu, Lesley Fallowfield, Prudence A. Francis, Sandra X. Franco Millan, Jenny Gilchrist, Joseph Gligorov, William J. Gradishar, Renate Haidinger, Nadia Harbeck, Xichun Hu, Ranjit Kaur, Belinda Kiely, Sung-Bae Kim, Smruti Koppikar, Marion J.J. Kuper-Hommel, Frédéric E. Lecouvet, Ginny Mason, Shirley A. Mertz, Volkmar Mueller, Claire Myerson, Silvia Neciosup, Birgitte V. Offersen, Shinji Ohno, Olivia Pagani, Ann H. Partridge, Frédérique Penault-Llorca, Aleix Prat, Hope S. Rugo, Elzbieta Senkus, George W. Sledge, Sandra M. Swain, Christoph Thomssen, Daniel A. Vorobiof, Peter Vuylsteke, Theresa Wiseman, Binghe Xu, Alberto Costa, Larry Norton, Eric P. Winer
Publikováno v:
Breast, Vol 76, Iss , Pp 103756- (2024)
This manuscript describes the Advanced Breast Cancer (ABC) international consensus guidelines updated at the last two ABC international consensus conferences (ABC 6 in 2021, virtual, and ABC 7 in 2023, in Lisbon, Portugal), organized by the ABC Globa
Externí odkaz:
https://doaj.org/article/de357938368a491d8c29ea9020d3b42e
Autor:
Stefania Morganti, Qingchun Jin, Julie Vincuilla, Ryan Buehler, Sean Ryan, Samantha Stokes, Tonia Parker, Elizabeth A. Mittendorf, Tari A. King, Anna Weiss, Ann H. Partridge, Brittany L. Bychkovsky, Giuseppe Curigliano, Nabihah Tayob, Nancy U. Lin, Judy E. Garber, Sara M. Tolaney, Filipa Lynce
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-6 (2024)
Abstract Following the survival benefit demonstrated in the OlympiA trial, one year of adjuvant olaparib is now recommended for all patients with germline BRCA1/2 pathogenic/likely pathogenic variants (PV) and high-risk, HER2-negative early breast ca
Externí odkaz:
https://doaj.org/article/a6787b2746714e679389db17fc729577
Autor:
Jorge Gómez Tejeda Zañudo, Romualdo Barroso-Sousa, Esha Jain, Qingchun Jin, Tianyu Li, Jorge E. Buendia-Buendia, Alyssa Pereslete, Daniel L. Abravanel, Arlindo R. Ferreira, Eileen Wrabel, Karla Helvie, Melissa E. Hughes, Ann H. Partridge, Beth Overmoyer, Nancy U. Lin, Nabihah Tayob, Sara M. Tolaney, Nikhil Wagle
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-19 (2024)
Abstract The landscape of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) resistance is still being elucidated and the optimal subsequent therapy to overcome resistance remains uncertain. Here we present the final results of a phase Ib/IIa, open-labe
Externí odkaz:
https://doaj.org/article/fbf0b09b34034b3ca24835f1877b47b7
Autor:
Samantha Mannion, Alexandra Higgins, Nicole Larson, Elizabeth A. Stewart, Zaraq Khan, Chandra Shenoy, Hazel B. Nichols, H. Irene Su, Ann H. Partridge, Charles L. Loprinzi, Fergus Couch, Janet E. Olson, Kathryn J. Ruddy
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Survey data from the Mayo Clinic Breast Disease Registry were used to assess fertility counseling and fertility preservation strategies in a modern cohort of young women with breast cancer. One hundred respondents were identified who were un
Externí odkaz:
https://doaj.org/article/86b7b4f987234257abdef6e562248c89
Publikováno v:
Breast, Vol 74, Iss , Pp 103700- (2024)
The results of several studies aiming to tailor early breast cancer treatment to individual risk were released in 2023. Axillary lymph node dissections and radiotherapy may be safely omitted in carefully selected patients. Sustained benefit from adju
Externí odkaz:
https://doaj.org/article/c94d6be8271a4c799fdeb8f0b6c0fe2b
Autor:
Elisabeth deKermadec, Yue Zheng, Shoshana Rosenberg, Kathryn J. Ruddy, Jennifer A. Ligibel, Karen M. Emmons, Ann H. Partridge
Publikováno v:
Cancer Medicine, Vol 13, Iss 1, Pp n/a-n/a (2024)
Abstract Background Diagnosis of breast cancer in young women has been shown to affect their decision‐making with regard to fertility and family planning. Limited data are available from populations across the U.S. regarding this issue; thus, we so
Externí odkaz:
https://doaj.org/article/3f1ac27d1df84e91ade86e3a07e48e7a
Autor:
Tal Sella, Yue Zheng, Shoshana M. Rosenberg, Kathryn J. Ruddy, Shari I. Gelber, Rulla M. Tamimi, Jeffrey M. Peppercorn, Lidia Schapira, Virginia F. Borges, Steven E. Come, Lisa A. Carey, Eric P. Winer, Ann H. Partridge
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-7 (2023)
Abstract Extended adjuvant endocrine therapy (eET) improves outcomes in breast cancer survivors. Most studies however have been limited to postmenopausal women, and optimal eET for young survivors is uncertain. We report eET use among participants in
Externí odkaz:
https://doaj.org/article/d8f59f34132643f3837f4026790bf189